An article in Kauppalehti suggests that Orion’s stock drop today is due to a sharp increase in research and development expenses. On the contrary, a long-term investor should be pleased with significant R&D boosts, especially in the pharmaceutical industry. Overall, it’s a solid, decent result, but I still need to look into the details.
10 Likes